These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 15961357

  • 1. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index.
    Genant HK, Siris E, Crans GG, Desaiah D, Krege JH.
    Bone; 2005 Aug; 37(2):170-4. PubMed ID: 15961357
    [Abstract] [Full Text] [Related]

  • 2. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
    Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH.
    Arch Intern Med; 2004 Oct 11; 164(18):2024-30. PubMed ID: 15477438
    [Abstract] [Full Text] [Related]

  • 3. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.
    Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH.
    Osteoporos Int; 2009 Jun 11; 20(6):943-8. PubMed ID: 18923884
    [Abstract] [Full Text] [Related]

  • 4. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
    Bouxsein ML, Chen P, Glass EV, Kallmes DF, Delmas PD, Mitlak BH.
    J Bone Joint Surg Am; 2009 Jun 11; 91(6):1329-38. PubMed ID: 19487509
    [Abstract] [Full Text] [Related]

  • 5. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
    Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M.
    J Clin Endocrinol Metab; 2012 Sep 11; 97(9):3097-106. PubMed ID: 22723322
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prognostic utility of a semiquantitative spinal deformity index.
    Crans GG, Genant HK, Krege JH.
    Bone; 2005 Aug 11; 37(2):175-9. PubMed ID: 15922683
    [Abstract] [Full Text] [Related]

  • 8. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH.
    J Bone Miner Res; 2006 Nov 11; 21(11):1785-90. PubMed ID: 17002571
    [Abstract] [Full Text] [Related]

  • 9. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.
    Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ.
    Bone; 2005 Jun 11; 36(6):948-58. PubMed ID: 15878318
    [Abstract] [Full Text] [Related]

  • 10. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.
    Harvey NC, Kanis JA, Odén A, Burge RT, Mitlak BH, Johansson H, McCloskey EV.
    Osteoporos Int; 2015 Nov 11; 26(11):2677-84. PubMed ID: 26092063
    [Abstract] [Full Text] [Related]

  • 11. Reduced risk of back pain following teriparatide treatment: a meta-analysis.
    Nevitt MC, Chen P, Dore RK, Reginster JY, Kiel DP, Zanchetta JR, Glass EV, Krege JH.
    Osteoporos Int; 2006 Feb 11; 17(2):273-80. PubMed ID: 16142502
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women.
    Oglesby AK, Minshall ME, Shen W, Xie S, Silverman SL.
    J Rheumatol; 2003 Jul 11; 30(7):1579-83. PubMed ID: 12858462
    [Abstract] [Full Text] [Related]

  • 15. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH.
    J Bone Miner Res; 2005 Sep 11; 20(9):1507-13. PubMed ID: 16059622
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.
    Krege JH, Wan X.
    Bone; 2012 Jan 11; 50(1):161-4. PubMed ID: 22036910
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec 11; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.